Angiogenin	O
is	O
up	O
-	O
regulated	O
in	O
the	O
nucleus	B-Cellular_component
and	O
cytoplasm	B-Organism_substance
in	O
human	O
primary	B-Cancer
breast	I-Cancer
carcinoma	I-Cancer
and	O
is	O
associated	O
with	O
markers	O
of	O
hypoxia	O
but	O
not	O
survival	O
.	O

Angiogenin	O
,	O
a	O
14	O
.	O
2	O
kD	O
polypeptide	O
that	O
was	O
originally	O
noted	O
for	O
its	O
angiogenic	O
activity	O
,	O
is	O
now	O
increasingly	O
recognized	O
to	O
have	O
a	O
multiplicity	O
of	O
biological	O
roles	O
in	O
both	O
physiological	O
and	O
pathological	O
conditions	O
.	O

In	O
breast	B-Cancer
cancer	I-Cancer
,	O
there	O
are	O
conflicting	O
studies	O
questioning	O
the	O
role	O
of	O
angiogenin	O
.	O

Here	O
,	O
the	O
pattern	O
of	O
expression	O
of	O
angiogenin	O
during	O
the	O
transition	O
from	O
normal	O
breast	B-Tissue
tissue	I-Tissue
to	O
ductal	B-Cancer
carcinoma	I-Cancer
in	I-Cancer
situ	I-Cancer
and	O
invasive	B-Cancer
carcinoma	I-Cancer
is	O
reported	O
together	O
with	O
the	O
correlates	O
between	O
the	O
level	O
of	O
angiogenin	O
in	O
239	O
invasive	B-Cancer
carcinomas	I-Cancer
and	O
standard	O
clinicopathological	O
parameters	O
,	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
-	O
1	O
alpha	O
and	O
the	O
HIF	O
-	O
1	O
alpha	O
target	O
gene	O
DEC	O
-	O
1	O
.	O

This	O
study	O
shows	O
that	O
angiogenin	O
expression	O
is	O
up	O
-	O
regulated	O
in	O
the	O
cytoplasmic	B-Cellular_component
and	O
nuclear	B-Cellular_component
compartments	I-Cellular_component
in	O
in	B-Cancer
situ	I-Cancer
carcinoma	I-Cancer
and	O
invasive	B-Cancer
carcinoma	I-Cancer
compared	O
with	O
normal	O
breast	B-Tissue
tissue	I-Tissue
and	O
that	O
angiogenin	O
expression	O
in	O
invasive	B-Cancer
carcinomas	I-Cancer
is	O
significantly	O
positively	O
associated	O
with	O
high	O
tumour	B-Cancer
grade	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
positive	O
oestrogen	O
receptor	O
(	O
ER	O
)	O
status	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
HIF	O
-	O
1	O
alpha	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
DEC	O
1	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
but	O
not	O
with	O
patient	O
age	O
(	O
p	O
=	O
0	O
.	O
8	O
)	O
,	O
tumour	B-Cancer
size	O
(	O
p	O
=	O
0	O
.	O
25	O
)	O
,	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
status	O
(	O
p	O
=	O
0	O
.	O
69	O
)	O
,	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
p	O
=	O
0	O
.	O
56	O
)	O
or	O
microvessel	B-Tissue
density	O
(	O
p	O
=	O
0	O
.	O
32	O
)	O
.	O

No	O
difference	O
in	O
relapse	O
-	O
free	O
(	O
p	O
=	O
0	O
.	O
26	O
)	O
or	O
overall	O
(	O
p	O
=	O
0	O
.	O
63	O
)	O
survival	O
was	O
observed	O
in	O
patients	O
stratified	O
by	O
angiogenin	O
expression	O
.	O

This	O
study	O
suggests	O
that	O
angiogenin	O
may	O
be	O
important	O
in	O
breast	B-Cancer
cancer	I-Cancer
progression	O
and	O
that	O
,	O
through	O
its	O
relationship	O
with	O
ER	O
,	O
it	O
may	O
be	O
a	O
target	O
for	O
tamoxifen	O
.	O

